Clay Reed is an Oncology physician affiliated with National Cancer Institute. OpenAlex indexes 12 publications with 404 citations (h-index 6).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Industry payments
19 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- AstraZeneca Pharmaceuticals LPProgram year20255 payments
- Novartis Pharmaceuticals CorporationProgram year202512 payments
- Caris MPI, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
49.3%Opioid Agonist25%Oxycodone Hcl92%Morphine Sulfate Er9%Part D<11 patientsPhenothiazine8.1%Prochlorperazine Maleate100%Part D≥46 patients+ 5 more classes in this area
Metabolism & gastrointestinal
16.7%Serotonin-3 Receptor Antagonist8%Ondansetron Odt100%Part D≥45 patientsCorticosteroid6%Prednisone100%Part D≥24 patients+ 1 more class in this area
Cancer & immunology
10.2%Antimetabolite3.3%Hydroxyurea100%Part D<11 patientsKinase inhibitor2.9%Kisqali100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Abstract A120: Sex differences in tolerability and response to immune checkpoint inhibitors in non-small cell lung cancer patients
Cancer Epidemiology Biomarkers & Prevention
2020
Similar KOLs
Other experts from the same institution or the same specialty.
Kevin Brown, MD
National Cancer Institute
James Gulley, MD
National Cancer Institute
Gregory Reaman, MD
National Cancer Institute
Robert Kreitman, MD
National Cancer Institute
Carl June, MD
University of Pennsylvania
Rainer Storb
University of Washington
Christina Fitzmaurice, MD
Beth Karlan, MD
University of California, Los Angeles
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”